NCT05407441 2026-04-13
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
7 trialsNCT05994235 2026-04-02
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06242834 2026-04-01
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Northwestern University
Phase 2 Active not recruiting
NCT05551936 2026-02-17
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
NCT04917042 2026-02-04
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
University of Florida
Phase 2 Active not recruiting
NCT04846478 2025-04-17
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02889523 2024-10-09
Epi-RCHOP
The Lymphoma Academic Research Organisation
Phase 1/2 Active not recruiting